Floatz logo

Hydrochlorothiazide

Cardiovascular Disorder

Tehran University of Medical SciencesSmall moleculePhase 4 / ApprovedDormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
89/ 100

Competitive context

55 Active assets in the Cardiovascular Disorder cohort.

Asset / SponsorPhaseRating
Aspirin
AstraZeneca
Phase 4BBB
Liraglutide
University of Sao Paulo General Hospital
Phase 4BBB
ATORVASTATIN
Duke University
Phase 4BBB
Rosuvastatin
Nanjing First Hospital, Nanjing Medical University
Phase 4BBB
SIMVASTATIN
McMaster University
Phase 4BBB

View all 50 →

Same molecule, other indications

Hydrochlorothiazide is also rated in:

hypertensive disorderActive
BBB
Indicative · Phase 4
77 / 100
View asset →
essential hypertensionActive
BBB
Indicative · Phase 4
77 / 100
View asset →
diabetes mellitusActive
BB
Indicative · Phase 4
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →